This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
AURA
A Phase 3 trial of belzupacap sarotalocan (AU-011) treatment versus sham in subjects with primary indeterminate lesions or small choroidal melanoma
Overview
The purpose of this research study is to test and determine how safe and how well bel-sar treatment works compared to sham (no medication or laser) in participants who have a type of eye cancer.
There will be three study arms. If you qualify, you will be randomly (like the toss of a coin) assigned to 1 of these 3 study arms:
- Participants in the first study arm will receive a high dose of the drug and will then receive the laser application.
- Participants in the second arm will receive a lower dose of the drug and will then receive the laser application.
- Participants in the third arm will receive a sham procedure defined as control arm (sham injection and sham laser application). The sham procedure will be the same as for the study drug and laser light application except that no study drug will be injected in the eye (only firm pressure to the eyeball will be applied with a needleless syringe) and no laser light will be applied during the sham laser procedure.
For further information about this study, please contact Cerulea on (03) 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Dr Rod O'Day
| The purpose of this research study is to test and determine how safe and how well bel-sar treatment works compared to sham (no medication or laser) in participants who have a type of eye cancer.
There will be three study arms. If you qualify, you will be randomly (like the toss of a coin) assigned to 1 of these 3 study arms:
For further information about this study, please contact Cerulea on (03) 8638 5300 or email info@ceruleaclinicaltrials.org.au |
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.